Drug Database · Clinicians

Lornoxicam

Brands (4) Laxico, Mosan, Zornica-4…Show all

Anti-inflamatory and antirheumatic; Non-steroidal anti-inflammatory drug (NSAID); and others PH FDA category

Avoid if CrCl <30Rx · Prescription drug4 PH products Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals

Contraindications

  • Severe kidney impairment (serum creatinine above 700 µmol/L)
  • Severe hepatic impairment
  • Severe heart failure
  • Active or recurrent peptic ulcer or bleeding
  • Thrombocytopenia
  • Third trimester of pregnancy
renalcarematters.com, reviewed

Dosing: Adult

  • Acute mild to moderate pain (Xefo Rapid tablets; arthritis regimens differ): 8 to 16 mg/day in 8 mg doses; 16 mg then 8 mg after 12 hours on day 1; maximum 16 mg/day thereafter
  • Kidney or hepatic impairment: Reduce to once-daily dosing (avoid at CrCl <30, our judgment)
renalcarematters.com, reviewed

Dosing: Altered kidney function

Lornoxicam is an oxicam nonsteroidal anti-inflammatory drug (NSAID) metabolized by CYP2C9; its pharmacokinetics change little in kidney failure, but NSAID effects on kidney blood flow still apply. The Irish label reduces dosing to once daily in kidney impairment and contraindicates it in severe impairment, defined by serum creatinine above 700 µmol/L. It has no US FDA label.

Kidney function measure: The SmPC grades kidney impairment by serum creatinine: mild 150–300 µmol/L (1.7–3.4 mg/dL), moderate 300–700 µmol/L (3.4–7.9 mg/dL), severe above 700 µmol/L (above 7.9 mg/dL). Bands are mapped to creatinine clearance (CrCl) by judgment; we advise avoiding it below CrCl 30.

Show full dosing details
CrCl ≥60 mL/min
Usual (acute pain): 8 to 16 mg/day in 8 mg doses; day 1 may be 16 mg then 8 mg 12 hours later; maximum 16 mg/day after day 1 (SmPC).
CrCl 30–59 mL/min
Kidney impairment: reduce dosing frequency to once daily (SmPC). Use with caution; stop if kidney function worsens.
CrCl 15–29 mL/min
Avoid. The SmPC contraindicates only at serum creatinine above 700 µmol/L (above 7.9 mg/dL), but that threshold is outdated; NSAIDs at CrCl <30 risk acute kidney injury, hyperkalemia and fluid overload (our judgment, consistent with other EU NSAID labels).
CrCl <15 mL/min (not on dialysis)
Avoid (our judgment: CrCl <30). Severe impairment (serum creatinine above 700 µmol/L [above 7.9 mg/dL]) is contraindicated in the SmPC.
Hemodialysis (intermittent)
Avoid: contraindicated in severe kidney impairment (SmPC). NSAIDs threaten residual kidney function.
Peritoneal dialysis
Avoid: contraindicated in severe kidney impairment (SmPC).
CRRT
Avoid; NSAIDs worsen acute kidney injury.
  • Dialyzable? Not stated (99% protein-bound).
  • Monitoring Kidney function in surgery, heart failure, diuretic or nephrotoxic co-therapy; stop if kidney function deteriorates. Hemoglobin, creatinine and liver enzymes regularly if used beyond 3 months (SmPC 4.4).
Children (kidney dosing)
eGFR ≥60
Not established in children; kidney dosing not applicable.
eGFR 30–59
Not established in children; kidney dosing not applicable.
eGFR 15–29
Not established in children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not established in children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not established in children; kidney dosing not applicable.
Peritoneal dialysis
Not established in children; kidney dosing not applicable.
CRRT
Not established in children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: HPRA (Ireland) product information (April 2015). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
Not recommended under 18 years (SmPC).
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Film-coated tablet: 4 mg, 8 mg
  • Lyophilized powder for injection: 8 mg

Registered products in the Philippines

4 products registered with the Food and Drug Administration (FDA) Philippines list Lornoxicam as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products4
Philippine FDA-registered products for Lornoxicam
Package insert
LaxicoLornoxicam
8 mg Film-Coated TabletWhite opaque PVC/PVDC/Alu blister packs x 10's (Box of 3 blister packs x 10 tablets)
Rx
Kusum Healthcare Pvt. Ltd.India
Kusum Healthcare Private Limited Branch Office
DR-XY48461
Nov 14, 2027
MosanLornoxicam
8 mg Lyophilized Powder for InjectionUSP Type I Amber Colored Glass Vial (as Active) + USP Type III Flint Glass Ampoule in 2 mL (as Diluent) in a box
Rx
Gufic Biosciences Ltd.India
SRS Life Sciences Inc.
DR-XY42158
Jun 25, 2028
Zornica-4Lornoxicam
4 mg Film-Coated TabletBlister Pack x 10's (Box of 30's)
Rx
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.
DR-XY44141
Jan 17, 2030
Zornica-8Lornoxicam
8 mg Film - Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.
DR-XY44243
Feb 24, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Other NSAIDs, corticosteroids, SSRIs, antiplateletsAvoidMore gastrointestinal bleeding.Avoid other NSAIDs; caution with the rest.
Warfarin and other anticoagulants; heparin with neuraxial anesthesiaAdjust or monitorMore bleeding; spinal or epidural hematoma.Monitor INR; caution with neuraxial procedures.
ACE inhibitors, ARBs, diuretics, beta-blockersAdjust or monitorLess blood-pressure effect; kidney injury and hyperkalemia.Monitor blood pressure, kidney function and potassium.
Methotrexate, lithium, cyclosporine, tacrolimus, digoxinAdjust or monitorHigher levels or toxicity.Monitor levels and kidney function.
SulfonylureasAdjust or monitorMore hypoglycemia.Monitor glucose.
CimetidineMinorHigher lornoxicam levels.Usually no action.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Nausea, abdominal pain, dyspepsia, diarrhea, vomiting
  • Headache, dizziness

Serious

  • Gastrointestinal bleeding and perforation
  • Thrombocytopenia, anemia
  • Acute kidney failure in pre-existing kidney impairment
  • Hepatotoxicity, hepatic failure
  • Stevens-Johnson syndrome, toxic epidermal necrolysis
renalcarematters.com, reviewed

Monitoring parameters

  • Kidney function in surgery, heart failure, diuretic or nephrotoxic co-therapy; stop if kidney function deteriorates. Hemoglobin, creatinine and liver enzymes regularly if used beyond 3 months (SmPC 4.4). Kidney
  • Kidney function in at-risk patients
  • Hemoglobin, creatinine and liver enzymes beyond 3 months
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

Bioavailability90% to 100%
Time to peakAbout 30 minutes (rapid tablet)
Half-life3 to 4 hours (5-hydroxy metabolite about 9 hours)
Half-life in kidney failure (ESKD) kidneyNo significant change in kidney failure (SmPC)
Protein binding99%
Metabolism (CYP, transporters)Hepatic CYP2C9 to inactive 5-hydroxylornoxicam
Renal excretion kidneyAbout 42% in urine (mainly metabolite), 50% in feces
Dialyzability kidneyNot stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Health Products Regulatory Authority (Ireland). Xefo Rapid 8 mg film-coated tablets SmPC (PA1547/005/004) [HPRA (Ireland) product information, April 2015; no US FDA label]. https://assets.hpra.ie/products/Human/28642/LicenseSPC_PA1547-005-004_11012017183040.pdf
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Takeda UK Limited. (2015). Xefo Rapid 8 mg film-coated tablets (lornoxicam) [Summary of product characteristics, licence PA1547/005/004; text revised April 2015]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/28642/LicenseSPC_PA1547-005-004_11012017183040.pdf

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .